MX2021016022A - Efecto sinergico de eyp001 e ifn para el tratamiento de la infeccion por hbv. - Google Patents

Efecto sinergico de eyp001 e ifn para el tratamiento de la infeccion por hbv.

Info

Publication number
MX2021016022A
MX2021016022A MX2021016022A MX2021016022A MX2021016022A MX 2021016022 A MX2021016022 A MX 2021016022A MX 2021016022 A MX2021016022 A MX 2021016022A MX 2021016022 A MX2021016022 A MX 2021016022A MX 2021016022 A MX2021016022 A MX 2021016022A
Authority
MX
Mexico
Prior art keywords
eyp001
treatment
ifn
synergistic effect
hbv infection
Prior art date
Application number
MX2021016022A
Other languages
English (en)
Inventor
Raphaël Darteil
Jacky Vonderscher
Elise Roy
Pietro Scalfaro
Original Assignee
Enyo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enyo Pharma filed Critical Enyo Pharma
Publication of MX2021016022A publication Critical patent/MX2021016022A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una combinación sinérgica de EYP001 e interferón para el tratamiento de la hepatitis B.
MX2021016022A 2019-07-18 2020-07-17 Efecto sinergico de eyp001 e ifn para el tratamiento de la infeccion por hbv. MX2021016022A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19186941 2019-07-18
PCT/EP2020/070241 WO2021009333A1 (en) 2019-07-18 2020-07-17 Synergistic effect of eyp001 and ifn for the treatment of hbv infection

Publications (1)

Publication Number Publication Date
MX2021016022A true MX2021016022A (es) 2022-02-03

Family

ID=67437952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021016022A MX2021016022A (es) 2019-07-18 2020-07-17 Efecto sinergico de eyp001 e ifn para el tratamiento de la infeccion por hbv.

Country Status (12)

Country Link
US (1) US20220313690A1 (es)
EP (1) EP3999069B1 (es)
JP (1) JP7376679B2 (es)
KR (1) KR102662826B1 (es)
CN (1) CN114051411B (es)
AU (1) AU2020314081A1 (es)
CA (1) CA3140325C (es)
ES (1) ES2968931T3 (es)
IL (1) IL289069B2 (es)
MX (1) MX2021016022A (es)
PL (1) PL3999069T3 (es)
WO (1) WO2021009333A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1238053C (zh) * 2002-12-02 2006-01-25 美德（江西）生物科技有限公司 含alfa－干扰素，拉米夫定和阿地福韦酯的药包
EP1886685A1 (en) * 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
CZ2007494A3 (cs) 2007-07-20 2008-11-12 Ceské vysoké ucení technické v Praze Optický clen pro rentgenovou mikroskopii
RU2013148779A (ru) * 2011-04-01 2015-05-10 Новартис Аг Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
CN105764569B (zh) * 2013-09-11 2019-09-13 国家医疗保健研究所 治疗乙型肝炎病毒感染的方法和药物组合物
US20220265817A1 (en) * 2017-05-31 2022-08-25 Arbutus Biopharma Corporation Therapeutic compositions and methods for treating hepatitis b
CN107441098A (zh) * 2017-06-28 2017-12-08 河南大学 Fxr拮抗剂在在制备抗hbv药物中的应用

Also Published As

Publication number Publication date
CN114051411A (zh) 2022-02-15
EP3999069B1 (en) 2023-10-11
CA3140325A1 (en) 2021-01-21
EP3999069C0 (en) 2023-10-11
US20220313690A1 (en) 2022-10-06
KR20220035437A (ko) 2022-03-22
ES2968931T3 (es) 2024-05-14
EP3999069A1 (en) 2022-05-25
PL3999069T3 (pl) 2024-03-25
IL289069B (en) 2022-11-01
IL289069B2 (en) 2023-03-01
CN114051411B (zh) 2022-10-28
KR102662826B1 (ko) 2024-05-03
WO2021009333A1 (en) 2021-01-21
JP2022540697A (ja) 2022-09-16
IL289069A (en) 2022-02-01
CA3140325C (en) 2022-07-19
JP7376679B2 (ja) 2023-11-08
AU2020314081A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
MX2022011756A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb.
MX2016009449A (es) Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb).
PH12020550531A1 (en) Novel, highly active pyrazolo-piperidine substituted indole2-carboxamides active against the hepatitis b virus (hbv)
PH12020550525A1 (en) Novel, highly active amino-thiazole substituted indole-2carboxamides active against the hepatitis b virus (hbv)
MX2021007602A (es) Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b.
MX2021014771A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.
IL280869A (en) Treatment of hepatitis delta virus infection with Lambda interferon
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
PH12019550039A1 (en) Dihydropyrimidine compound and preparation method and use thereof
PH12021551369A1 (en) Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same
EP4037706A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
IL288019A (en) Preparations and methods for treating hepatitis b virus infection
MX2023008365A (es) Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
MX2022002231A (es) Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b.
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
MX2022000742A (es) Metodo para disminuir los efectos adversos del interferon.
MX2021013085A (es) Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb).
MX2021016022A (es) Efecto sinergico de eyp001 e ifn para el tratamiento de la infeccion por hbv.
MX2022007909A (es) Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
EP3894402C0 (en) N-CONTAINING CHROMEN-4-ON DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION